Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585750 | 0.94 | OPRD1 (0.64) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL8892422 | 0.90 | OPRD1 (0.66) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL236139 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL236138 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4576571 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL233715 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4575507 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4575467 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL18661816 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL233716 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | disclosed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | VERSI GROUP, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007027987-A2 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2300/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2300/4885 |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2300/4885 |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.